Hydrogel film loaded with antibacterial agent as well as preparation method and application of hydrogel film

By using hydrogel films loaded with antibacterial agents, the shortcomings of traditional dressings in hemostasis and chronic wound treatment are overcome, achieving a multi-functional effect of rapid hemostasis, anti-infection and promoting healing, while reducing the risk of bacterial resistance.

CN120837715APending Publication Date: 2025-10-28EAST CHINA UNIV OF SCI & TECH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202510989285.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-17
Publication Date
2025-10-28

AI Technical Summary

Technical Problem

Existing wound dressings have limited hemostatic effects in the treatment of acute and chronic wounds, are difficult to regulate the complex pathophysiological microenvironment of infected chronic wounds, and antibiotic use leads to increased bacterial resistance, hindering the healing process.

Method used

A hydrogel film loaded with an antibacterial agent was developed by forming a hydrogel network by mixing polyethylene glycol monomers and polyphenols with different end groups. The antibacterial agent was loaded to promote hemostasis, anti-infection and promote healing, and is suitable for the treatment of acute and chronic wounds.

Benefits of technology

It achieves rapid hemostasis in acute wounds, antioxidant and anti-infection effects in chronic wounds, promotes the wound healing process, reduces the risk of bacterial resistance, and provides a simplified treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005505356960000021
    Figure BDA0005505356960000021
  • Figure BDA0005505356960000031
    Figure BDA0005505356960000031
  • Figure BDA0005505356960000032
    Figure BDA0005505356960000032
Patent Text Reader

Abstract

The invention discloses a hydrogel film loaded with an antibacterial agent as well as a preparation method and application of the hydrogel film. Specifically, the hydrogel film disclosed by the invention is prepared from the following raw materials: two or more polyethylene glycol monomers with different end groups, polyphenol substances and an antibacterial agent. The hydrogel film loaded with the antibacterial agent has good hemostatic performance in acute wound nursing, has good anti-infection, anti-oxidation and wound healing promoting performance in chronic infection wound nursing, and has good biocompatibility in the environments of wounds, blood and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of hydrogel film dressings. Specifically, this invention relates to hydrogel films loaded with antibacterial agents, their preparation methods, and applications. Background Technology

[0002] The wound healing process includes hemostasis, inflammation, reepithelialization, angiogenesis, collagen deposition, and matrix remodeling. Ideal wound dressings should support the entire wound healing process to aid in hemostasis and tissue regeneration. Uncontrolled bleeding from acute wounds accounts for 50% of all wartime deaths and 39% of civilian trauma deaths, making it a leading cause of trauma-related deaths; therefore, hemostasis in acute wounds is crucial. Furthermore, the incidence of chronic wounds caused by chronic diseases such as diabetes is increasing. The persistent exudate in chronic wounds exacerbates the accumulation of reactive oxygen species (ROS) and bacterial colonization, synergistically hindering the healing process. The persistent ROS accumulation in chronic wounds maintains a persistent inflammatory microenvironment that impairs wound healing by damaging cell function, disrupting extracellular matrix remodeling, and activating matrix metalloproteinases and pro-inflammatory cytokines. Bacterial infection triggers the massive recruitment of neutrophils and macrophages. These cells, in the process of clearing pathogens, exacerbate oxidative damage by excessively producing ROS, potentially leading to tissue necrosis and progression to life-threatening sepsis. In addition, bleeding may occur during the treatment of chronic wounds, which further complicates the treatment process.

[0003] Clinical practice and basic research have shown that the treatment of acute wounds includes pressure to stop bleeding, bandaging, debridement, antibiotic treatment and suturing, while the standard treatment for chronic wounds usually includes debridement of necrotic tissue, skin grafting, application of topical antibiotics, negative pressure wound therapy, hyperbaric oxygen therapy and wound dressing.

[0004] Among the aforementioned approaches, wound dressing therapy offers several significant advantages, including simplified treatment protocols, reduced patient pain, and lower healthcare costs. While traditional dressings (such as gauze and bandages) have been used clinically for decades, their hemostatic effects are limited, and they are insufficient to modulate the complex pathophysiological microenvironment in infected chronic wound models. Furthermore, the use of antibiotics can lead to bacterial resistance, posing a greater challenge to wound treatment.

[0005] Therefore, there is an urgent need in this field to develop a type of hydrogel dressing with multiple active functions, good biocompatibility, and simple preparation process for wound care and treatment. Summary of the Invention

[0006] One object of the present invention is to provide a multifunctional hydrogel film that can be used for hemostasis of acute bleeding wounds and for anti-oxidation, anti-infection and promotion of chronic wound healing in chronic wounds.

[0007] Another object of the present invention is to provide a hydrogel film loaded with an antibacterial agent for use in hemostasis of acute bleeding wounds and for anti-oxidation, anti-infection and promotion of chronic wound healing in chronic wounds.

[0008] In a first aspect of the present invention, a hydrogel film loaded with an antibacterial agent is provided, wherein the constituent raw materials of the hydrogel film include: two or more polyethylene glycol monomers with different end groups, polyphenolic substances and antibacterial agents;

[0009] Wherein, the polyethylene glycol monomer is a linear, multi-arm polyethylene glycol monomer; and the number of arms is any value between 2 and 22; and each of the polyethylene glycol monomers is independently selected from the following group:

[0010]

[0011] m represents the chain length, where each m is an independent positive integer between 4 and 10000; q represents The number of times a unit is repeated; and q is an integer from 1 to 20;

[0012] A is * indicates a connection point;

[0013] R is an end group of a polyethylene glycol monomer; and each of them is independently a reactive group selected from the group consisting of: amino, C1-C15 alkylamino, acylhydrazine, C1-C15 alkylhydrazine, aldehyde, C1-C15 alkyl-aldehyde, mercapto, C1-C15 alkyl-mercapto, C2-C15 alkenyl, C1-C15 alkyl-norbornenyl, C1-C15 alkyl-maleimide, C1-C15 alkyl-aminothiol, C2-C15 alkynyl, and C1-C15 alkyl-azido.

[0014] The end groups of two or more polyethylene glycol monomers with different end groups react to form a hydrogel network; and the polyphenolic substances and antibacterial agents are distributed on the hydrogel network.

[0015] In another preferred embodiment, the two or more polyethylene glycol monomers with different end groups refer to two or more polyethylene glycol monomers with different end groups that are capable of reacting.

[0016] In another preferred embodiment, each of the polyethylene glycol monomers is independently selected from the group consisting of:

[0017]

[0018] R, A, and m are as described above.

[0019] In another preferred example, q is an integer between 4 and 12.

[0020] In another preferred embodiment, the number of arms of the polyethylene glycol monomer is 2, 4, 8, 10, or 14.

[0021] In another preferred embodiment, the polyphenolic substances include natural and synthetic polyphenolic substances; preferably, the polyphenolic substances are selected from the group consisting of phenolic acids, flavonoids, stilbenes, lignans, tannins, or combinations thereof.

[0022] In another preferred embodiment, the polyphenolic substance is selected from the group consisting of tannic acid, tea polyphenols, catechins, epigallocatechin gallate, tea polyphenols, proanthocyanidins, resveratrol, or combinations thereof.

[0023] In another preferred embodiment, the antibacterial agent is selected from the group consisting of: polypeptide polymers, β-lactam antibiotics (such as penicillins and cephalosporins), aminoglycoside antibiotics (such as streptomycin and amikacin), quinolone antibiotics (such as first-, second-, third-, and fourth-generation quinolones), macrolide antibiotics (such as erythromycin and azithromycin), polypeptide antibiotics (such as vancomycin and polymyxin B), tetracycline antibiotics (such as tetracycline and oxytetracycline), chloramphenicol antibiotics (such as chloramphenicol and thiamphenicol), sulfonamide antibiotics (such as sulfadiazine and sulfamethoxazole), rifamycin (such as rifampin and rifapentine), or combinations thereof;

[0024] The polypeptide polymer is a homopolymer containing β-lysine residues or a copolymer containing β-lysine residues and β-glycine residues.

[0025] In another preferred embodiment, the polypeptide polymer has the structure shown in Formula I:

[0026]

[0027] in,

[0028] The compound of formula I has an L, D, or DL ​​configuration;

[0029] a is a positive integer between 0 and 100;

[0030] n is a positive integer between 5 and 5000;

[0031] 0%<x<100%, 0%<y<100%, and x+y=100%;

[0032] R zSelected from the following groups: halogen, carboxyl, active ester group (-NHS active ester or maleimide active ester and its derivatives), acyl chloride (-(C=O)Cl), epoxy alkyl (-CH(=O)CH-), mercapto, C2-C15 alkenyl, C2-C15 alkynyl, azide, maleimide, o-dithiopyridyl (OPSS), cyclodextrin, adamantyl;

[0033] R w for The wavy line indicates the connection point.

[0034] In another preferred embodiment, the content of the polyphenolic substance in the hydrogel film is 0 wt% to 200 wt%, based on the weight of the hydrogel film.

[0035] In another preferred embodiment, the antibacterial agent content in the hydrogel film is 0wt%-10wt%, based on the weight of the hydrogel film.

[0036] In another preferred embodiment, the content of the polyphenolic substance in the hydrogel film is 1-150 wt%; more preferably 2-100 wt%; 2.5-50 wt%; and even more preferably 5-20 wt%, based on the mass of the hydrogel film.

[0037] In another preferred embodiment, the antibacterial agent content in the hydrogel film is 0-50 wt%; more preferably 0.25-10 wt%; more preferably 0.5-4 wt%; and even more preferably 1-2 wt%, based on the mass of the hydrogel film.

[0038] In another preferred embodiment, the hydrogel film exhibits a release performance of 200-250 μg / mL in a buffer solution at pH 8.5 within 120 minutes.

[0039] In another preferred embodiment, the hydrogel film exhibits a release performance of 10-100 μg / mL in a pH 5.5 buffer solution over 120 minutes.

[0040] In another preferred embodiment, the hydrogel film has a release performance of 1-250 μg / mL within 120 minutes; more preferably 10-150 μg / mL; and even more preferably 50-100 μg / mL.

[0041] In another preferred embodiment, the tensile strength of the hydrogel film is 0.2 ± 0.04 MPa.

[0042] In another preferred embodiment, the elongation at break of the hydrogel film is 118.39 ± 10.20%.

[0043] In another preferred embodiment, the hydrogel film can be cut into any shape according to the area and shape of the wound.

[0044] In a second aspect of the present invention, a method for preparing the hydrogel film described in the first aspect of the present invention is provided, comprising the steps of:

[0045] (1) Provides a solution A of polyethylene glycol monomer A in a protic solvent, and a solution B of polyethylene glycol monomer B in a protic solvent, wherein the polyethylene glycol monomer A and polyethylene glycol monomer B are different from each other and are each independently selected from the group consisting of:

[0046]

[0047] m represents the chain length, where each m is an independent positive integer between 4 and 10000; q represents The number of times a unit is repeated; and q is an integer from 1 to 20;

[0048] A is * indicates a connection point;

[0049] R is an end group of a polyethylene glycol monomer; and each of them is independently a reactive group selected from the group consisting of: amino, C1-C15 alkylamino, acylhydrazine, C1-C15 alkylhydrazine, aldehyde, C1-C15 alkyl-aldehyde, mercapto, C1-C15 alkyl-mercapto, C2-C15 alkenyl, C1-C15 alkyl-norbornenyl, C1-C15 alkyl-maleimide, C1-C15 alkyl-aminothiol, C2-C15 alkynyl, and C1-C15 alkyl-azido.

[0050] (2) The solutions A and B are mixed to form a hydrogel precursor solution; wherein the hydrogel precursor solution includes an unformed hydrogel precursor formed by polyethylene glycol monomer A and polyethylene glycol monomer B;

[0051] (3) Add polyphenols and an antibacterial agent to the hydrogel precursor solution to obtain a hydrogel film precursor; and

[0052] (4) Dry the hydrogel film precursor to obtain a hydrogel film.

[0053] In another preferred embodiment, for each polyethylene glycol monomer, each end group R is either the same or different.

[0054] In another preferred embodiment, each end group R is identical for each polyethylene glycol monomer.

[0055] In another preferred embodiment, R is each independently a reactive group selected from the group consisting of: amino, C1-C10 alkylamino, hydrazide, C1-C10 alkylhydrazide, aldehyde, C2-C10 alkylaldehyde, mercapto, C1-C10 alkylthiol, C2-C10 alkenyl, C1-C10 alkyl-norbornenyl, C1-C10 alkyl-maleimide, C1-C10 alkyl-aminothiol, C2-C10 alkynyl, and C1-C10 alkyl-azido.

[0056] In another preferred embodiment, R is an independent amino group, a C1-C6 alkylene amino group, an acylhydrazine, a C1-C6 alkylene acylhydrazine, an aldehyde group, a C2-C6 alkylene aldehyde group, a mercapto group, a C1-C6 alkylene mercapto group, a C2-C6 alkenyl group, a C1-C6 alkylene-norbornenyl group, a C1-C6 alkylene-maleimide group, a C1-C6 alkylene-aminothiol group, a C2-C6 alkynyl group, or a C1-C6 alkylene-azido group.

[0057] In another preferred embodiment, in step (1), the proton solvent is selected from the group consisting of C1-C6 alcohol solvents; more preferably, the proton solvent is selected from the group consisting of ethanol (preferably a 50%-90% aqueous ethanol solution).

[0058] In another preferred embodiment, in step (1), the mass fraction of polyethylene glycol monomer A in solution A is 0.1-20 wt%; more preferably 1-10 wt%; more preferably 1-5 wt%; and even more preferably 2.5-5 wt%.

[0059] In another preferred embodiment, in step (1), the mass fraction of polyethylene glycol monomer B in the solution B is 0.1-20 wt%; more preferably 1-10 wt%; more preferably 1-5 wt%; and even more preferably 2.5-5 wt%.

[0060] In another preferred embodiment, the polyethylene glycol monomer A and polyethylene glycol monomer B have the same number of arms.

[0061] In another preferred embodiment, the number of arms of the polyethylene glycol monomer A is half the number of arms of the polyethylene glycol monomer B.

[0062] In another preferred embodiment, in step (2), the volumes of solution A and solution B are the same.

[0063] In another preferred embodiment, in step (2), the solutions A and B are mixed in a ratio of 1:(1±0.1) of the molar ratio of the end groups (arms) in the polyethylene glycol monomers.

[0064] In another preferred embodiment, in step (2), the hydrogel precursor solution includes an unformed polyethylene glycol solid formed by mixing polyethylene glycol monomer A and polyethylene glycol monomer B at room temperature, i.e., the hydrogel precursor.

[0065] In another preferred embodiment, in step (2), the mass percentage of the hydrogel precursor in the hydrogel precursor solution is 1wt%-100wt%; more preferably 1wt%-50wt%; more preferably 1%-20wt%; more preferably 1wt%-10wt%; and even more preferably 1wt%-5wt%.

[0066] In another preferred embodiment, in step (2), the mixing temperature is room temperature; more preferably 5-40°C; and even more preferably 20-40°C.

[0067] In another preferred embodiment, in step (2), the mixing time is 1-48h; more preferably 18-36h; and even more preferably 24-36h.

[0068] In another preferred embodiment, in step (3), the polyphenolic substance is dissolved in a proton solvent and then added to the hydrogel precursor solution, or the polyphenolic substance is directly added to the hydrogel precursor solution.

[0069] In another preferred embodiment, in step (3), the antibacterial agent is dissolved in a proton solvent and then added to the hydrogel precursor solution, or the antibacterial agent is directly added to the hydrogel precursor solution.

[0070] In another preferred embodiment, in step (3), the amount of polyphenols added to the hydrogel precursor solution is 0.1-10 wt%; more preferably 0.2-5 wt%; and even more preferably 0.25-2 wt%, calculated based on the total mass of the hydrogel precursor solution.

[0071] In another preferred embodiment, in step (3), the amount of antibacterial agent added to the hydrogel precursor solution is 0-0.5 wt%; more preferably 0.0025-0.25 wt%; more preferably 0.01-0.2 wt%; more preferably 0.01-0.1 wt%; more preferably 0.02-0.05 wt%, calculated based on the total mass of the hydrogel precursor solution.

[0072] In another preferred embodiment, in step (4), the drying refers to removing the proton solvent from the hydrogel film precursor to obtain a hydrogel film loaded with an antibacterial agent.

[0073] In another preferred embodiment, step (4) further includes, prior to drying, coating the hydrogel film precursor onto the surface.

[0074] In another preferred embodiment, step (4) further includes:

[0075] Hydrogel film precursors are coated onto a surface by spraying, spin coating, or dip coating and then evaporated and dried to obtain a hydrogel film.

[0076] In another preferred embodiment, the spraying refers to applying the hydrogel film precursor to the surface using pressure spraying, centrifugal spraying, airflow spraying, ultrasonic spraying, and ionization spraying, or a combination thereof.

[0077] In another preferred embodiment, the evaporation refers to natural evaporation, heated evaporation, vacuum distillation, or a combination thereof.

[0078] In another preferred embodiment, spin coating refers to uniformly applying the hydrogel film precursor onto a surface to form a film by high-speed rotation, including the use of a spin coating device.

[0079] In another preferred embodiment, dip coating refers to immersing the surface in a hydrogel film precursor to form a film, including the use of dip coating equipment.

[0080] In a third aspect of the invention, the use of the hydrogel film loaded with an antibacterial agent as described in the first aspect of the invention is provided for the preparation of wound dressings.

[0081] In another preferred embodiment, the wound dressing is used for hemostasis, physical isolation, chronic wound care, promoting wound healing, or a combination thereof.

[0082] In another preferred embodiment, the physical isolation refers to covering the wound surface to isolate dust and bacteria and / or reduce the risk of pathogen infection.

[0083] In another preferred embodiment, promoting wound healing means promoting wound tissue regeneration, promoting wound closure, and promoting the regeneration of normal physiological tissues.

[0084] In another preferred embodiment, promoting wound healing means promoting the closure of wound tissue and achieving anatomical and functional integrity.

[0085] In another preferred embodiment, promoting wound healing refers to removing wound exudate, providing antioxidant protection to the wound, isolating the wound, keeping the wound dry, and preventing infection, or a combination thereof.

[0086] In another preferred embodiment, the wound antioxidant refers to the elimination of reactive oxygen species and reactive nitrogen species in the wound tissue.

[0087] In another preferred embodiment, the anti-infection refers to reducing and / or eliminating pathogenic bacterial infection at the wound site.

[0088] In another preferred embodiment, the promotion of wound tissue regeneration includes promoting granulation tissue formation, collagen deposition, and epithelial cell regeneration.

[0089] In another preferred embodiment, the chronic wound care refers to descaling wound exudate, wound anti-oxidation, wound isolation, keeping wound dry, anti-infection, or a combination thereof.

[0090] In another preferred embodiment, the wound is an acute wound and / or a chronic wound caused by an accident or disease.

[0091] In another preferred embodiment, the wound is an acute wound, a chronic wound, or a combination thereof.

[0092] In another preferred embodiment, the acute wound is selected from the group consisting of: physical trauma (including burns and frostbite), traumatic bleeding wounds, preoperative or postoperative wounds resulting from medical procedures, or combinations thereof.

[0093] In another preferred embodiment, the chronic wound is selected from the group consisting of: pressure ulcers, diabetic ulcers, lower extremity vascular ulcers (including arterial and venous ulcers), traumatic ulcers, infected ulcers (including grade C wounds), tumor-induced wounds, wounds caused by connective tissue diseases (such as leprosy), or combinations thereof.

[0094] In another preferred embodiment, the pressure ulcer includes stage I (congestion and redness stage), stage II (inflammatory infiltration stage), stage III (superficial ulcer stage), stage IV (deep ulcer stage), unstageable stage, and deep tissue injury stage.

[0095] In another preferred embodiment, the chronic wound includes chronic infected wounds and chronic non-healing wounds.

[0096] In another preferred embodiment, the chronic infected wound includes diabetic infected wounds, including type 1 diabetic infected wounds and type 2 diabetic infected wounds.

[0097] In another preferred embodiment, the chronic wound is infected with pathogenic bacteria, and the pathogenic bacteria are Gram-positive bacteria, Gram-negative bacteria, fungi, or combinations thereof; preferably, the pathogenic bacteria are selected from the group consisting of aerobic bacteria, anaerobic bacteria, or combinations thereof; more preferably, the pathogenic bacteria are selected from the group consisting of Staphylococcus aureus, vancomycin-resistant enterococci, hemolytic streptococci, Staphylococcus epidermidis, Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, Cryptococcus neoformans, Candida albicans, Candida glabrata, or combinations thereof.

[0098] In a fourth aspect of the invention, a hydrogel film dressing is provided, comprising:

[0099] (1) The hydrogel film loaded with antibacterial agent as described in the first aspect of the present invention

[0100] (2) Solid support; and

[0101] (3)Optionally, other active ingredients that promote wound healing and / or recovery.

[0102] In another preferred embodiment, the other active ingredients are selected from the group consisting of fibroblast growth factor, platelet-derived growth factor, transforming growth factor-β, vascular endothelial growth factor, keratinocyte growth factor, silicone, growth factor EGF, hyaluronic acid, collagen, or combinations thereof.

[0103] In another preferred embodiment, the solid support is selected from the group consisting of: films, fibers, and gauze.

[0104] In another preferred embodiment, the method for preparing the hydrogel film dressing includes:

[0105] The hydrogel film is bonded to the solid support to obtain a hydrogel film dressing.

[0106] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0107] Figure 1 The image shows the XPS test results for the hydrogel film.

[0108] Figure 2 The image shows the SEM test results of the hydrogel film.

[0109] Figure 3 The image shows the EDS test results of the hydrogel film.

[0110] Figure 4 Figure 1 shows the tensile strength test results of the hydrogel film. (a) is a schematic diagram of the hydrogel film tensile strength test; (b) are representative tensile curves of hydrogel films with different TA contents; (c) are the maximum tensile strengths of hydrogel films with different TA contents; and (d) are the elongation at break of hydrogel films with different TA contents.

[0111] Figure 5 Figure 1 shows the results of the shear adhesion test of the hydrogel film. (a) is a schematic diagram of the shear adhesion test between the hydrogel film and pigskin; (b) are representative shear adhesion curves of hydrogel films with different TA contents; and (c) shows the adhesion strength of hydrogel films with different TA contents to pigskin.

[0112] Figure 6The study tested the antibacterial activity of the polypeptide polymer βLys50HG50 against a variety of Gram-positive / negative pathogens (including multidrug-resistant strains isolated clinically), with the antibiotics ampicillin and levofloxacin serving as controls.

[0113] Figure 7 Image showing the antibacterial live / dead staining microscopy results of a hydrogel film loaded with polypeptide polymers.

[0114] Figure 8 The graph shows the quantitative results of the antibacterial activity of the hydrogel film loaded with polypeptide polymer.

[0115] Figure 9 The results show the cytotoxicity test results of the hydrogel film loaded with peptide polymer. Among them, the results of the MTT assay for cytotoxicity are shown after co-incubation with the hydrogel film dressing extract for (a) 24 hours, (b) 48 hours and (c) 72 hours.

[0116] Figure 10 Hemolytic toxicity of hydrogel films loaded with polypeptide polymers.

[0117] Figure 11 The release curves of the hydrogel film loaded with polypeptide polymers are shown.

[0118] Figure 12 The result is the removal of intracellular reactive oxygen species generated by lipopolysaccharide (LPS) stimulation by hydrogel films loaded with polypeptide polymers.

[0119] Figure 13 The figures show the hemostasis results of a hydrogel film loaded with polypeptide polymers in an in vivo model of acute liver injury and bleeding. (a) The hydrogel film adheres to the liver wound and is easily removed after hemostasis. (b) The hemostatic effects of various hydrogel films with different components and the positive control (Medtronic hemostatic sponge, merocel) within 0–240 seconds; the wound was left untreated as a negative control (blank). (c) The weight of blood lost during hemostasis using various hydrogel films with different components, the positive control, and the negative control.

[0120] Figure 14 The results of using a hydrogel film loaded with polypeptide polymers to remove reactive oxygen species (ROS) from in vivo wounds are shown in the images. (a) Fluorescence imaging of ROS in mouse in vivo wounds and surrounding tissues after different treatments, using an in vivo imaging system and fluorescence confocal microscopy. (b) Quantitative analysis of the fluorescence intensity of ROS in mouse in vivo wounds and surrounding tissues.

[0121] Figure 15Figure 1 shows the results of using a hydrogel film loaded with polypeptide polymers to remove exudate from a wound. (a) Schematic diagram of the modeling of an infected diabetic wound and the quantitative analysis of exudate after treatment with the hydrogel film dressing. (b) Results of different treatment time points using normal saline (negative control) and Botansu (B. Braun, ...). Representative photographs of exudate accumulation in different infectious diabetic wounds after treatment with positive control and hydrogel film (PG-TA-P). (c) At different treatment time points, using normal saline (negative control), Botansu (B. Braun, Quantitative analysis of exudate from different infectious diabetic wounds after treatment with positive control and hydrogel film (PG-TA-P).

[0122] Figure 16 This study demonstrates the in vivo antibacterial effect of hydrogel films loaded with polypeptide polymers. (a) Schematic diagram of the modeling and treatment with hydrogel film dressings for diabetic infectious wounds. (b) Representative images (LB agar plates) of surviving bacterial colonies in wound tissue 24 hours after treatment with PBS, pure PEG hydrogel (PG), TA-doped PEG hydrogel (PG-TA), and polypeptide polymer-doped PG-TA hydrogel (PG-TA-P). (c) Bacterial load analysis and (d) Histological analysis of Gram-stained sections of treated infectious diabetic wounds. Botansu served as a positive control, and physiological saline as a negative control.

[0123] Figure 17 This image shows the effect of hydrogel films loaded with polypeptide polymers on promoting wound healing in vivo. (a) and (b) are photographs of diabetic infected wounds and schematic diagrams showing changes in wound area at different time points after treatment. (c) shows the healing rate of diabetic infected wounds treated with saline, Pronto, and PG-TA-P hydrogel wound dressings during the wound healing process. (d) Representative Masson trichrome stained images of infected diabetic wounds 9 days after treatment with saline, Pronto, and PG-TA-P hydrogel wound dressings, respectively. Detailed Implementation

[0124] Through extensive and in-depth research, the inventors unexpectedly discovered a polyethylene glycol hydrogel that can be easily prepared, and introduced polyphenols and antibacterial agents into it, thereby giving the resulting hydrogel film better mechanical properties, adhesion properties, and antibacterial properties. Because the hydrogel precursor prepared by mixing the two polyethylene glycol monomer solutions of this invention retains good fluidity, the hydrogel film can be prepared on a substrate by spraying or spin coating, and the hydrogel film layer is formed after the solvent evaporates. Furthermore, the dried gel film after evaporation facilitates long-term medical storage and transportation, and can be cut into suitable shapes according to the shape and area of ​​the wound for application. Based on these findings, the inventors completed this invention.

[0125] the term

[0126] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0127] As used herein, when referring to a specific enumerated value, the term “about” means that the value can vary by no more than 1% from the enumerated values. For example, as used herein, the expression “about 100” includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0128] As used herein, the terms “containing” or “including (comprise)” can be open-ended, semi-closed, or closed. In other words, the terms also include “consistently made of” or “composed of”.

[0129] Throughout this specification, the terms “optionally substituted” or “substituted or unsubstituted” indicate that the group may be further substituted or fused with one or more non-hydrogen substituents (to form a polycyclic system). Substituents for suitable chemically appropriate specific functional groups will be apparent to those skilled in the art.

[0130] As used in this text, the term "C1-C6 alkyl" refers to a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.

[0131] As used in this text, the term "C1-C6 alkoxy" refers to straight-chain or branched alkoxy groups having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, hexoxy, etc.

[0132] As used in this text, the term "C1-C15 alkyleneamino" refers to a group formed by replacing one hydrogen atom in a straight-chain or branched (usually straight-chain) C1-C15 alkyl group with an amino group (usually at the end of the alkyl chain), for example, -(CH2). p -NH2, p is an integer from 1 to 15. Other groups have similar definitions, for example, C1-C10 alkyleneamino, C1-C6 alkyleneamino.

[0133] As used in this text, the term "acylhydrazine" refers to a substance with... Groups in the structure.

[0134] As used in this text, the term "C1-C15 alkylene hydrazide" refers to a group formed by replacing one hydrogen atom in a straight-chain or branched (usually straight-chain) C1-C15 alkyl group with an hydrazide (usually at the end of the alkyl chain), for example, -(CH2). p -C(O)NH-NH2, p is an integer from 1 to 15. Other groups have similar definitions.

[0135] As used in this text, the term "aldehyde" refers to the -CHO group.

[0136] As used in this text, the term "C1-C15 alkylene-aldehyde" refers to a group formed by replacing one hydrogen atom in a straight-chain or branched (usually straight-chain) C1-C15 alkyl group with an aldehyde group (usually substituted at the end of the alkyl chain), for example, -(CH2). p -CHO, where p is an integer from 2 to 15. Other groups have similar definitions.

[0137] As used in this text, the term "thiol" refers to the -SH group.

[0138] As used in this text, the term "C1-C15 alkylene mercapto" refers to a group formed by replacing one hydrogen atom in a straight-chain or branched (usually straight-chain) C1-C15 alkyl group with a mercapto group (usually substituted at the end of the alkyl chain), for example, -(CH2). p -SH, where p is an integer from 1 to 15. Other groups have similar definitions.

[0139] As used in this text, the term "C2-C15 alkenyl" refers to a straight-chain or branched hydrocarbon group having 2-15 carbon atoms and a reactive free double bond at the end. Other groups have similar definitions.

[0140] As used in this text, the term "C2-C15 ynyl group" refers to a straight-chain or branched hydrocarbon group having 2-15 carbon atoms and a reactive free carbon-carbon triple bond at the end. Other groups have similar definitions.

[0141] As used in this text, the term "C1-C15 alkylene-norbornenyl" refers to a straight-chain or branched (usually straight-chain) C1-C15 alkyl group in which one hydrogen atom is surrounded by a norbornenyl group. The wavy line indicates a substituent group formed at the junction (usually at the end of an alkyl chain), for example, -(CH2). p -norbornenyl, p is an integer from 1 to 15. Other groups have similar definitions.

[0142] As used in the text, the term "maleimide group" refers to... The wavy line indicates the connection point.

[0143] As used in this text, the term "C1-C15 alkylene-maleimide" refers to a group formed by replacing one hydrogen atom in a straight-chain or branched (usually straight-chain) C1-C15 alkyl group with a maleimide group (usually substituted at the end of the alkyl chain), for example, -(CH2). p - Maleimide group, p is an integer from 1 to 15. Other groups have similar definitions.

[0144] As used in this text, the term "aminothiol" refers to... Groups, with wavy lines indicating connections.

[0145] As used in this text, the term "C1-C15 alkylene-aminothiol" refers to a group formed by replacing one hydrogen atom in a straight-chain or branched (usually straight-chain) C1-C15 alkyl group with an aminothiol (usually substituted at the end of the alkyl chain), for example, -(CH2). p -Aminothiol, p is an integer from 1 to 15. Other groups have similar definitions.

[0146] As used in the text, the term "azido" refers to... Groups, with wavy lines indicating connections.

[0147] As used in this text, the term "C1-C15 alkylene-azido" refers to a group formed by replacing one hydrogen atom in a straight-chain or branched (usually straight-chain) C1-C15 alkyl group with an azide group (usually substituted at the end of the alkyl chain), for example, -(CH2). p -Azide group, p is an integer from 1 to 15. Other groups have similar definitions.

[0148] The structural formula or name of the polypeptide polymer given in this invention may only be an example of a specific configuration or may not be given. The polypeptide polymer may also include all other configurations corresponding to the given configuration.

[0149] antimicrobial agents

[0150] To enhance the wound-healing effect of the hydrogel film, an antibacterial agent is incorporated during the preparation process. There are no particular limitations on the antibacterial agents used in the hydrogel system of this invention, including those known in the art that have antibacterial activity against anaerobic bacteria, aerobic bacteria (including Gram-positive and Gram-negative bacteria), and other fungi, including but not limited to: β-lactam antibiotics (such as penicillins and cephalosporins), aminoglycoside antibiotics (such as streptomycin and amikacin), quinolone antibiotics (such as first-, second-, third-, and fourth-generation quinolones), macrolide antibiotics (such as erythromycin and azithromycin), polypeptide antibiotics (such as vancomycin and polymyxin B), tetracycline antibiotics (such as tetracycline and oxytetracycline), chloramphenicol antibiotics (such as chloramphenicol and thiamphenicol), sulfonamide antibiotics (such as sulfadiazine and sulfamethoxazole), rifamycin (such as rifampin and rifapentine), or combinations thereof.

[0151] polypeptide polymers

[0152] Specifically, the polypeptide polymer in this invention is a homopolymer containing β-lysine residues or a copolymer containing β-lysine and β-glycine residues, and is a β-polypeptide polymer. Preferably, the polypeptide polymer used in this invention has the structure shown in Formula I; more preferably, the β-polypeptide polymer is:

[0153]

[0154] The polypeptide polymers of the present invention can be obtained by conventional experimental methods in the art, or by methods disclosed in patent literature. For example, polypeptide polymers can be prepared by the method disclosed in application number 202210686387.5, the entire text of which is incorporated herein by reference.

[0155] The polypeptide polymer described in this invention has good biocompatibility and no obvious hemolytic activity against human erythrocytes, mouse erythrocytes, etc.; and no obvious cytotoxicity against mammalian cells such as mouse embryonic fibroblasts, African monkey kidney cells, human umbilical vein endothelial cells, canine kidney cells, etc.

[0156] hydrogel film

[0157] The present invention provides a hydrogel film loaded with an antibacterial agent, the composition of which includes a polyethylene glycol polymer, a polyphenolic substance and an antibacterial agent.

[0158] The hydrogel film of the present invention is based on a hydrogel matrix in which polyphenols and antibacterial agents are uniformly distributed.

[0159] The hydrogel film of the present invention is prepared using two polyethylene glycol monomers with different end groups. Specifically, the polyethylene glycol monomers are linear, multi-armed polyethylene glycol monomers; and the number of arms is any value between 2 and 22; each polyethylene glycol monomer is independently selected from the following group:

[0160]

[0161] m represents the chain length, where each m is an independent positive integer from 4 to 10000 (preferably m is an integer from 4 to 5000; for example, 10, 50, 100, 150, 200, 400, 800, 1500, 3000, 4500, etc.); q represents The number of times a unit is repeated; and q is an integer from 1 to 20;

[0162] A is * indicates a connection point;

[0163] R is an end group of a polyethylene glycol monomer; and each of them is independently a reactive group selected from the group consisting of: amino, C1-C15 alkylamino (-(CH2)p-NH2, p being an integer from 1 to 15), hydrazide, C1-C15 alkylhydrazide, aldehyde, C1-C15 alkyl-aldehyde, mercapto, C1-C15 alkyl-mercapto, C2-C15 alkenyl, C1-C15 alkyl-norbornenyl, C1-C15 alkyl-maleimide, C1-C15 alkyl-aminothiol, C2-C15 alkynyl, and C1-C15 alkyl-azido.

[0164] It can be seen that the end groups of the polyethylene glycol monomers of the present invention are reactive groups. The formation of the hydrogel network from the polyethylene glycol monomers of the present invention is not achieved through a rapid click chemical reaction. The reaction process of the end groups of the polyethylene glycol is relatively slow. Thanks to the fact that the hydrogel precursor solution prepared by mixing the two polyethylene glycols does not form a three-dimensional network hydrogel and retains good fluidity, the hydrogel precursor solution can be spread on a substrate by spraying or spin coating, and a dry gel film is formed after solvent evaporation. Furthermore, the dried gel film after evaporation facilitates long-term medical storage and transportation, and can be prepared and cut into suitable hydrogel film shapes according to the size, shape, and area of ​​the wound. This hydrogel film differs from traditional hydrogels in that it can be stored dry without shrinking into a hard lump due to water loss or internal structural collapse that would hinder clinical use.

[0165] Furthermore, the hydrogel film prepared from polyethylene glycol monomers exhibits excellent swelling properties, capable of absorbing 1300% of its own weight in liquid. This means that when used as a wound dressing, this hydrogel film can absorb exudate. The surface of the hydrogel film prepared from polyethylene glycol monomers displays a crater-like microstructure with nanoscale cavities. After absorbing water and swelling, the fracture surface of the hydrogel film shows a uniformly distributed cross-linked network structure, thus exhibiting excellent release properties. Polymer release results show that the hydrogel film releases 200-250 μg / mL in a pH 8.5 aqueous buffer solution within 120 minutes; and 10-100 μg / mL in a pH 5.5 buffer solution within 120 minutes.

[0166] This invention discovers that adding polyphenolic substances during the preparation of hydrogel films can improve the mechanical and tensile properties of the hydrogel. Polyphenolic substances that can be added to hydrogel films include, but are not limited to, natural and synthetic polyphenolic substances known in the art, such as phenolic acids, flavonoids, stilbenes, lignans, tannins, or combinations thereof; more specifically, for example, tannic acid, tea polyphenols, catechins, epigallocatechin gallate, tea polyphenols, proanthocyanidins, resveratrol, or combinations thereof.

[0167] In one specific embodiment, the mass percentage of the polyphenolic substance in the hydrogel film is not particularly limited. The amount of polyphenolic substance added can be adjusted according to the mechanical and tensile properties of the hydrogel film (or hydrogel dressing) required by the wound and wound site, as well as the application time requirements. Generally, the mechanical and tensile properties increase with the increase of the amount of polyphenolic substance added. For example, the polyphenolic substance content is 1-150 wt%; preferably 2-100 wt%; 2.5-50 wt%; more preferably 5-20 wt%, based on the mass of the hydrogel film.

[0168] To further accelerate wound healing and improve repair capabilities, antibacterial agents are added during the preparation of the hydrogel film, thereby achieving an antibacterial effect on wound healing, especially in chronic wounds. There are no particular limitations on the antibacterial agents that can be used in the hydrogel film of this invention, including but not limited to artificial and natural antibiotics already disclosed and commonly used in the art, such as levofloxacin, and peptide polymers with antibacterial properties may also be used.

[0169] In one specific embodiment, the mass percentage of the antibacterial agent in the hydrogel film is not particularly limited. The amount and type of antibacterial agent added to the hydrogel film (or hydrogel film dressing) can be adjusted according to the severity of the wound, the wound recovery time, the wound infection status, etc. For example, the content of the antibacterial agent in the hydrogel film is 0-50 wt%; preferably 0.25-10 wt%; more preferably 0.5-4 wt%; and even more preferably 1-2 wt%, based on the mass of the hydrogel film.

[0170] The hydrogel film of this invention can be directly used as a dressing for wounds, or fixed to the wound surface using medical devices such as adhesive tape. It can also be further combined with commonly used solid carriers for dressings to create portable dressing products. During the preparation of the dressing product, other commonly used active ingredients that promote wound healing and recovery can be added, such as silicone, EGF (epidermal growth factor), hyaluronic acid, fibroblast growth factor, platelet-derived growth factor, transforming growth factor-β, vascular endothelial growth factor, keratinocyte growth factor, collagen, or combinations thereof.

[0171] This invention does not impose any particular requirements on the preparation method of dressings of various forms. They can be prepared using methods commonly used in the art, or by referring to the methods in the embodiments of this invention.

[0172] use

[0173] This invention provides a hydrogel film loaded with an antibacterial agent, which can be used as a dressing on its own, or combined with other dressing matrices and other active ingredients that can be used to promote wound healing to prepare a hydrogel film dressing for promoting wound healing.

[0174] In this invention, a wound refers to an injured or broken area, primarily referring to the skin, muscles, mucous membranes, etc., of humans or other animals. Wounds are generally classified into acute wounds and chronic wounds based on their healing time. Acute wounds mainly refer to sudden injuries (such as wounds within 7 days of injury), such as abrasions, chafing, scratches, and puncture wounds. Chronic wounds (i.e., difficult-to-heal wounds) refer to acute wounds that fail to heal according to the body's normal physiological mechanisms due to various reasons, resulting in prolonged healing. Generally, from a medical perspective, wounds that fail to heal for more than a month are called chronic wounds or difficult-to-heal wounds. Causes of chronic wounds include (but are not limited to): injuries caused by pressure (such as bedsores), ulcers caused by varicose veins or insufficient arterial blood supply, diabetic ulcers, etc.; or atypical wounds caused by various diseases such as skin and soft tissue infections, vascular inflammation, connective tissue diseases, and tumors; wounds with poor prognosis due to long-term radiation exposure leading to tissue necrosis and infection.

[0175] Preferably, the wound can be (but is not limited to): chronic non-healing wounds caused by traumatic ulcers, chronic non-healing wounds caused by pressure ulcers (such as pressure sores), and chronic non-healing wounds caused by arterial ulcers (such as diabetic ulcers), vascular (such as venous) ulcers, pressure sores, fistulas and sinuses, and other skin or mucosal injuries.

[0176] In another preferred embodiment, the repair / healing of refractory wounds includes improving wound healing rate and / or shortening wound healing time to achieve anatomical and functional integrity.

[0177] In this invention, wound healing refers to promoting wound tissue regeneration, promoting wound tissue closure, and achieving a state of anatomical and functional integrity. For example, compared with not using the hydrogel film or the hydrogel film dressing of this invention, the wound healing rate using the hydrogel film or the hydrogel film dressing of this invention is increased and / or the healing time is shortened by 10%, 20%, 50%, or even 100%; or the hydrogel film or the hydrogel film dressing of this invention repairs wounds that cannot be repaired by other conventional wound-healing drugs.

[0178] Experiments have demonstrated that the hydrogel film or hydrogel film dressing of the present invention has the following uses: clearing wound exudate, anti-oxidation of wounds, isolating wounds, keeping wounds dry, and fighting infection; promoting cell proliferation and / or migration; promoting angiogenesis; anti-inflammatory; inhibiting biofilms; and / or repairing skin and / or mucous membrane damage. Through these multiple activities and functions, wound healing can be significantly promoted.

[0179] In another preferred embodiment, the hydrogel film dressing further includes a solid carrier for loading or fixing the hydrogel film, such as medical gauze, cotton swabs, cotton balls, cotton pads, adhesive tape, plastic stickers, etc.

[0180] The present invention also provides a method for promoting wound healing, the method comprising the step of: contacting the hydrogel film (or hydrogel film dressing) described in the first aspect of the present invention with a wound, thereby promoting wound healing.

[0181] Compared with the prior art, the main advantages of the present invention include:

[0182] (1) This invention develops a polyethylene glycol hydrogel that can slowly form a solid structure. By introducing polypeptide polymers into the hydrogel precursor solution, a hydrogel film with high antibacterial activity is obtained. Polyphenols are introduced to increase the mechanical and adhesive properties of the hydrogel film. Finally, a hydrogel film wound dressing loaded with antibacterial agent is obtained that can be used for hemostasis of acute wounds and care of chronic infected wounds to promote healing.

[0183] (2) The hydrogel film wound dressing loaded with antibacterial agent of the present invention can quickly adhere to, seal and stop bleeding in acute wounds.

[0184] (3) The hydrogel film wound dressing loaded with antibacterial agent of the present invention has high antibacterial activity against Staphylococcus aureus and other bacteria in chronic infected wounds and is not easy to induce bacteria to develop drug resistance. It has a good scavenging effect on reactive oxygen and reactive nitrogen in chronic wounds, which can reduce the inflammatory burden in wounds and promote the healing of chronic wounds and the regeneration of normal physiological tissues in wounds.

[0185] (4) The hydrogel film wound dressing loaded with antibacterial agent of the present invention has good biocompatibility.

[0186] (5) The hydrogel film loaded with antibacterial agent of the present invention is convenient for long-term medical storage and transportation. At the same time, it can be cut into a suitable shape according to the shape and area of ​​the wound for application. As a dressing, it can be suitable for wounds of various shapes and application scenarios.

[0187] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.

[0188] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as are familiar to those skilled in the art. Furthermore, any methods and materials similar to or equivalent to those described herein may be applied to the methods of this invention. The preferred embodiments and materials described herein are for illustrative purposes only.

[0189] Example 1: Random β-amino acid copolymers were prepared by co-initiating β-lactam monomers Lys and HG with 2-(triphenylmethylthio)acetic acid-N-succinimide ester and hexamethyldisilamide amino lithium salt.

[0190]

[0191] Weigh the Lys and HG monomers in a nitrogen-protected glove box. Using dry tetrahydrofuran (THF) as solvent, add 1 mL of Lys (0.2 M) and 1 mL of HG (0.2 M) solution to a reaction flask with a pre-added stir bar and stir. Then, prepare 100 μL each of p-2-(triphenylmethylthio)acetic acid-N-succinimide ester (0.02 M) and hexamethyldisilamide amino lithium salt (0.05 M) as co-initiators and quickly add them to the reaction flask. React at room temperature for 4 hours. Remove the reaction flask from the glove box and quench the reaction with 50 μL of methanol. Then, transfer the reaction solution to a 50 mL centrifuge tube with THF. Add 45 mL of ice-cold petroleum ether to the reaction solution. After a white flocculent precipitate forms, collect it by centrifugation, remove the supernatant, redissolve it with 1.5 mL of THF, and precipitate it again with petroleum ether. After repeating this process three times, a protected polymer was obtained and placed in a vacuum drying apparatus for 4 hours to completely remove the organic solvent. Then, trifluoroacetic acid (2 mL) was added to the protected, dried polymer to dissolve it, resulting in a bright yellow clear liquid. 40 μL of triethylsilane (esi) was then added, resulting in a colorless, clear, and transparent liquid. The liquid was shaken for 2 hours to remove the Boc protecting group. After rotary evaporation to remove most of the trifluoroacetic acid, 45 mL of methoxymethyl tert-butyl ether was added to precipitate a white precipitate. The precipitate was collected by centrifugation, and the supernatant was removed. The precipitate was then redissolved in 1.5 mL of methanol and precipitated again with 45 mL of methoxymethyl tert-butyl ether. This process was repeated three times. The remaining solvent was then removed using a vacuum drying apparatus. The samples were then dissolved in ultrapure water (5 mL) and filtered through a 0.45 μm syringe filter to remove impurities. Finally, the deprotected random β-amino acid copolymer was obtained by lyophilization (yield 80%, GPC characterization chain length 18 mere).

[0192] Example 2: Preparation of hydrogel films

[0193] 2.1 Preparation of PEG-based hydrogel films

[0194] Polyethylene glycol (PEG)-based hydrogel films (PEG-Gel, PG) are prepared by forming dynamic covalent Schiff base bonds between the amino and aldehyde groups of the four-arm PEG. Four-arm PEG-NH2 and four-arm PEG-CHO were dissolved in 90% ethanol (2.5%, 5.0%, and 10.0% by mass), respectively, and sterilized by passing through a 0.22 μm filter membrane. The two PEG solutions were mixed in equal volumes and allowed to stand at 37°C for 24 hours to generate a hydrogel precursor through the reaction of the amino and aldehyde groups. The hydrogel precursor was uniformly sprayed onto a PTFE mold and evaporated under vacuum at 80°C for 10 minutes to remove the ethanol, finally obtaining the PEG hydrogel film PEG-Gel (PG2.5, PG5, and PG10 represent PEG hydrogel films with a total PEG solids content of 2.5 wt%, 5 wt%, and 10 wt%, respectively).

[0195] 2.2 Preparation of tannic acid (TA)-doped PEG-based hydrogel films

[0196] The preparation method of tannic acid (TA)-introduced polyethylene glycol (PEG) film (PG-TA) is similar to that described in the previous section. 4-arm PEG-NH2 and 4-arm PEG-CHO were dissolved in 90% ethanol (5.0 wt%) to obtain clear solutions, which were then sterilized by passing through a 0.22 μm filter membrane. Equal volumes of the two PEG solutions were mixed and allowed to stand at 37°C for 24 hours to generate a hydrogel precursor through the reaction of amino and aldehyde groups. TA solution (50 mg / mL, 90% ethanol) was added to the hydrogel precursor to achieve a TA concentration of 10 mg / mL (1.0 wt%, the percentage of TA in the solid content of polyethylene glycol, the same below), resulting in a tannic acid (TA)-doped PEG-based hydrogel. The tannic acid (TA)-doped PEG-based hydrogel was uniformly sprayed onto a PTFE mold and evaporated under vacuum at 80°C for 10 minutes to remove ethanol, finally obtaining the TA-doped PEG hydrogel film PG-TA.

[0197] 2.3 Preparation of PEG-based hydrogel films loaded with peptide polymers

[0198] The preparation method of the polypeptide polymer-supported film (PG-TA-P, PEG solid content 5.0 wt%, TA content 1.0%, polypeptide polymer concentration 400 μg / mL) is similar to that described in the previous section. 4-arm PEG-NH2 and 4-arm PEG-CHO were dissolved in 90% ethanol (5.0 wt%, PG5) and sterilized by passing through a 0.22 μm filter membrane. Equal volumes of the two PEG solutions were mixed and incubated at 37°C for 24 hours, generating a hydrogel precursor through the reaction of amino and aldehyde groups. A TA solution (50 mg / mL, 90% ethanol) and a polypeptide polymer solution (4 mg / mL, 90% ethanol) were added to the hydrogel precursor to achieve a TA concentration of 10 mg / mL (1.0 wt%) and a polypeptide polymer concentration of 400 μg / mL (1.0 wt%, the percentage of polypeptide polymer in the polyethylene glycol solid content, the same below), yielding a polypeptide polymer-doped hydrogel. The polypeptide polymer-doped hydrogel was uniformly sprayed onto a PTFE mold, and then vacuum evaporated at 80°C for 10 minutes to remove ethanol, finally obtaining a polypeptide polymer-doped hydrogel film PG-TA-P. A PEG-based hydrogel film loaded with polypeptide polymers, with a PEG solid content of 5.0 wt% and a TA content of [missing information]. 1.0 wt%, with a polypeptide polymer content of 400 μg / mL. ).

[0199] Example 3: Characterization of hydrogel films

[0200] To demonstrate the successful preparation of the hydrogel film and the successful incorporation of the peptide polymer, the morphology and elemental distribution of the hydrogel film were measured using scanning electron microscopy (SEM) and energy dispersive spectroscopy (EDS).

[0201] The preparation method of the films was similar to that described in Example 2, with tannin content of 0 wt%, 0.25 wt%, 0.5 wt%, 1.0 wt%, and 2.0 wt%. These films were immersed in Mili-Q water for 1 hour to reach swelling equilibrium. Subsequently, these hydrogel films were lyophilized and observed by SEM. The original films were dried in a drying oven for 3 days, and their elemental distribution, elemental composition, and non-covalent coordination relationships were characterized by EDS and XPS, respectively. The distribution of the fluorescently labeled polypeptide polymer (FITC-βLys50HG50, 50 μg / mL) in the hydrogel films was studied by confocal laser scanning microscopy (LSCM) to further verify the spatial uniformity of βLys50HG50.

[0202] The characterization results of the hydrogel film are as follows: Figure 1-3 As shown, Figure 1 XPS test results for polypeptide polymer-doped polyethylene glycol-tannic acid (PG-TA-P) hydrogel films; Figure 2 The image shows the SEM test results of hydrogel films (PG, PG-TA 0.5%, PG-TA 1.0%, PG-TA-P). It can be seen that the hydrogel film dressing has a porous microstructure, indicating that the hydrogel film dressing can realize the rapid diffusion and exchange of peptide polymers, which is beneficial to the antibacterial effect of antimicrobial peptide polymers. Figure 3 The image shows the EDS test results of a polypeptide polymer-doped polyethylene glycol-tannic acid (PG-TA-P) hydrogel film dressing, indicating that the polypeptide polymer β-Lys 50 HG 50 They are evenly distributed in the hydrogel film.

[0203] Example 4: Mechanical strength of hydrogel film dressings loaded with peptide polymers

[0204] To characterize the tensile strength and elongation at break of the hydrogel films, hydrogel film dressings with different compositions were tested using a dynamic biomaterials mechanical testing system (ElectroForce 3200 series, USA). All mechanical tests were performed after the original film had been completely converted into a hydrogel film. The mechanical properties of PG5 films with different TA contents (0.25%, 0.5%, and 1.0%) were tested, with the PG5 film serving as a control group. The preparation methods for PG5-TA0.25, PG5-TA0.5, and PG5-TA1.0 films were similar to those described in the previous section. Hydrogel films were prepared into specimens with a thickness of 0.4 mm, a width of 2.5 mm, and a length of 8 mm for tensile property testing. Tensile tests were performed at a fixed rate of 3 mm / min. Tensile strength was calculated based on the tensile force at break, and elongation at break was recorded during the tensile test.

[0205] The results are as follows Figure 4 As shown, Figure 4 A schematic diagram of the hydrogel film tensile strength test is shown; Figure 4 b shows representative tensile curves of hydrogel films with tannin content of 0 wt%, 0.25 wt%, 0.5 wt%, and 1.0 wt%, indicating that the tensile strength of the hydrogel film increases with increasing tannin content; Figure 4 c shows the maximum tensile strength of hydrogel films with tannic acid contents of 0 wt%, 0.25 wt%, 0.5 wt%, and 1.0 wt%, which increased from 0.06 ± 0.01 MPa to 0.2 ± 0.04 MPa, respectively, indicating that the maximum tensile strength of the hydrogel film increases with the increase of tannic acid content. Figure 4 Figure d shows the elongation at break of hydrogel films with tannic acid contents of 0 wt%, 0.25 wt%, 0.5 wt%, and 1.0 wt%, which are 30.0 ± 12.3%, 104.7 ± 3.3%, 116.9 ± 13.0%, and 118.4 ± 10.2%, respectively, indicating that the elongation at break of the hydrogel films increases with the increase of tannic acid content.

[0206] Example 5: Adhesion strength of hydrogel film dressings loaded with peptide polymers

[0207] Due to the biological similarity between pigskin and human skin, it is considered a representative material for human skin. The shear adhesion strength between the bio-adhesive and pigskin was evaluated according to ASTM F2255-05 standard.

[0208] Before testing, subcutaneous fat and hair were removed from fresh pigskin. The pigskin was cut into 20mm × 50mm rectangular pieces and washed three times with ethanol and PBS, respectively. A hydrogel film was uniformly sprayed onto the pigskin to form a 20mm × 20mm bonding area, and a stress of 5N was applied to the pigskin for 10 minutes to prepare the test sample.

[0209] The peel bond strength between the bio-adhesive and pigskin was evaluated according to ASTM F2256-05. Subcutaneous fat and hair were removed from fresh pigskin prior to testing. The pigskin was cut into 20mm × 50mm rectangular segments and washed three times with ethanol and PBS, respectively. A hydrogel film was uniformly sprayed onto the pigskin surface to form an 8mm × 8mm bonding area, and a pressure of 5N was applied to the pigskin surface for 10 minutes to prepare the test sample. Adhesion strength testing was performed using a dynamic biomaterials mechanical testing system (ElectroForce 3200 series, USA) at room temperature with a loading rate of 3mm / min until the substrate material completely separated.

[0210] The results are as follows Figure 5 As shown, Figure 5 A schematic diagram of the shear adhesion test between the hydrogel film and pigskin is shown; Figure 5 b shows representative shear adhesion curves of hydrogel films with tannin content of 0.25 wt%, 0.5 wt%, and 1.0 wt%, indicating that the adhesion of the hydrogel film to pigskin increases with increasing tannin content. Figure 5 c shows the adhesion strength of hydrogel films with tannin content of 0.25 wt%, 0.5 wt%, and 1.0 wt% to pigskin, with results of 3.28 ± 0.28 kPa, 3.96 ± 0.20 kPa, and 5.37 ± 0.65 kPa, respectively, indicating that the adhesion strength of hydrogel films to pigskin increases with increasing tannin content.

[0211] Example 6: Antibacterial Activity Test of Peptide Polymers

[0212] The polypeptide polymer synthesized in Example 1 was used as an antibacterial agent, and the commercially available clinical antibiotics ampicillin and levofloxacin were used as controls for antibacterial activity testing. The selected bacterial strains included Gram-positive and Gram-negative bacteria. The Gram-positive bacteria were methicillin-resistant Staphylococcus aureus Sa USA300 LAC, vancomycin-resistant Enterococcus VRE 01, and Staphylococcus epidermidis Se 0692; the selected Escherichia coli were E. coli 25922, clinically ampicillin-resistant E. coli E. coli 2904, clinically ampicillin-resistant Pseudomonas aeruginosa Pa 0507, clinically ampicillin-resistant Klebsiella pneumoniae Kp 1904, clinically ampicillin-resistant Acinetobacter baumannii Ab 0403, and clinically ampicillin-resistant Acinetobacter baumannii A.b1712. These strains were all obtained from the American Type Culture Collection (ATCC) and Ruijin Rehabilitation Hospital in Shanghai.

[0213] Antimicrobial activity is expressed as the minimum inhibitory concentration (MIC), and the following testing method is mainly used. First, each bacterium is cultured for 10 hours in a shaker at a suitable temperature for its corresponding growth stage using appropriate culture media. Once the bacteria reach maturity, they are transferred to a centrifuge and centrifuged at 4000 rpm for 5 minutes. The supernatant is discarded, and the bacteria at the bottom are dispersed with a small amount of test culture medium. The OD value is measured on a microplate reader, and the bacterial suspension is diluted to 2 × 10⁵ CFU / mL based on the OD value. 10 μL of the polymer at a concentration of 4 mg / mL is added to the first well of a 96-well plate, followed by 90 μL of culture medium. Then, 50 μL of the solution is serially diluted from row B to row H, and 50 μL of the bacterial suspension is added to each well. The culture medium serves as a negative control, and the bacterial suspension as a positive control. After incubation at a suitable temperature for the corresponding bacterial strain for 9 hours, the 96-well plate is read at a wavelength of 600 nm using a microplate reader. Finally, the bacterial growth rate % was calculated according to the formula: (OD polymer - OD blank) / (OD control - OD blank) × 100%. In the antibacterial activity test, each sample had two replicates and the experiment was repeated three times.

[0214] The antibacterial activities of the synthesized polypeptide polymer, antibiotics ampicillin, and levofloxacin against various bacterial species in Example 1 are as follows: Figure 6 As shown. Antibacterial test results show that the polypeptide polymer of the present invention exhibits excellent antibacterial activity against multiple multidrug-resistant Gram-positive and Gram-negative bacteria, with both the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) below 25 μL / mL. Its antibacterial activity against Staphylococcus epidermidis is comparable to that of the control antibiotics ampicillin and levofloxacin, and its antibacterial activity against most other bacterial species is significantly superior to clinically used ampicillin and comparable to that of clinically used levofloxacin.

[0215] Example 7: Release experiment of polypeptide polymer from hydrogel

[0216] The polypeptide polymer βLys from Example 1 was selected. 50 HG 50 Characterize the release behavior of polypeptide polymers from PG-TA-P films.

[0217] The tests were performed in different buffer solutions at pH 5.5, 7.0, and 8.5. After complete swelling equilibration, the hydrogel films were immersed in 0.4 mL buffer solutions at pH 5.5, 7.0, and 8.5, and gently shaken at 60 rpm. At predetermined time intervals, 20 μL of the solution was collected from the samples and diluted with PBS. β-Lys in the sample solutions... 50 HG 50The concentration was detected by the fluorescent amine method. The absorbance of the solution was measured using a SpectraMax M2 microplate reader (excitation wavelength λ = 380 nm, emission wavelength λ = 475 nm), and the concentration was calibrated using an established standard curve.

[0218] The release effect of peptide polymers from hydrogels is as follows Figure 11 As shown, βLys 50 HG 50 It exhibited pH-dependent release kinetics, including a burst release at pH 8.5, with a cumulative release concentration of 226.32 ± 11.77 μg / mL within 40 minutes, and sustained release at pH 7.0 and 5.5, with cumulative release concentrations of 141.19 ± 16.96 μg / mL and 67.79 ± 7.88 μg / mL within 24 hours, respectively.

[0219] Example 8: Antibacterial activity test of hydrogel films loaded with peptide polymers

[0220] The in vitro antibacterial activity of the hydrogel film was evaluated using Gram-positive Staphylococcus aureus Sa USA300LAC and Gram-negative Escherichia coli E. coli 25922 as representative pathogens.

[0221] The preparation method of the hydrogel film is similar to that described in Example 2. In short, 100 μL of the hydrogel film precursor solution (PEG solid content of 5.0 wt%) was placed in a 2.0 mL centrifuge tube, and ethanol was evaporated under vacuum at 80 °C for 10 minutes to obtain hydrogel films (PG hydrogel (PEG solid content of 5.0 wt%), PG-TA hydrogel (PEG solid content of 5.0 wt%, TA content of 1.0 wt%), PG-TA-P hydrogel (PEG solid content of 5.0 wt%, TA content of 1.0 wt%, polypeptide polymer content of 400 μL / mg)). Subsequently, 100 μL of phosphate buffered saline (PBS) solution was added to the tube to swell the film.

[0222] The bacteria were cultured in Luria-Bertani (LB) medium at 37°C with continuous shaking for 10 hours. After centrifugation, the bacterial suspension was washed with PBS and diluted to 5 × 10⁻⁶ with PBS. 6 The working suspension was prepared using CFU / mL. 100 μL of the bacterial working suspension was added to a tube and incubated with the hydrogel membrane at 37°C for 6 hours. The mixture was then collected and homogenized with Triton X-100 (0.1% concentration in PBS). The homogenate was serially diluted on LB agar plates and incubated at 37°C for 14 hours. The antibacterial effect was assessed by counting the number of colonies on the plates.

[0223] The bacterial culture for the live / dead staining experiment was performed using a similar method as described above. 100 μL of bacterial working suspension was added to a tube and incubated with a hydrogel membrane at 37°C for 6 hours, followed by sonication for 2 minutes. After removing the membrane, the bacteria were collected by centrifugation and resuspended in PBS. The live / dead staining experiment used SYTO 9 (green) / PI (red) staining at concentrations of 8 μM and 25 μg / mL, respectively. Images were acquired using a fluorescence microscope.

[0224] like Figure 7 As shown in the microscopic images of the antibacterial live / dead staining of the polypeptide polymer-doped hydrogel films, the PG-TA-P hydrogel film dressing almost completely killed the bacteria, with only red fluorescence in the fluorescence images indicating dead bacteria in the MRSA and E. coli communities. In contrast, the PG and PG-TA hydrogel groups showed abundant green fluorescence in their fluorescence images, indicating that the MRSA and E. coli communities were essentially alive and had no antibacterial ability. Figure 8 As shown, the quantitative antibacterial experiment of the hydrogel film indicated that there were almost no bacteria on the LB agar plates treated with PG-TA-P, while a large number of bacteria remained on the LB agar plates treated with PG and PG-TA hydrogel films, showing no significant difference compared to the PBS treatment. Quantitative colony counting results showed that the number of bacterial colonies in the PG-TA-P hydrogel film group was significantly reduced (4.75 log CFU less for MRSA and 5.13 log CFU less for E. coli compared to the PBS control group), while the number of bacterial colonies in the PG5 and PG5-TA groups showed no significant difference compared to the PBS treatment.

[0225] Example 9: Cytotoxicity test of hydrogel films loaded with peptide polymers

[0226] Hydrogel films were prepared using the polypeptide polymer obtained in Example 1, and their cytotoxicity against human umbilical vein endothelial cells (HUVEC), NCTC clone 929 (L929), mouse embryonic fibroblasts (NIH-3T3), and African green monkey kidney fibroblasts (COS-7) was tested.

[0227] The hydrogel membrane was pre-soaked in 0.5 mL of DMEM medium for 12 hours, and the extract was used for cytotoxicity testing. The monolayer of cells was first digested with trypsin, and after cell detachment, the cells were collected and centrifuged at 1200 rpm for 4 minutes to deposit the cells. The supernatant was discarded, and the cells were resuspended in culture medium for counting. The cells were then diluted to 8 × 10⁶ cells / mL with the 24-hour extract. 4 Cells / mL were transferred to 96-well plates at a rate of 100 μL per well. The 96-well plates were then incubated at 37°C with 5% CO2 for a period of time for live / dead cell staining and microscopic observation.

[0228] The MTT quantification assay was performed as follows: The culture medium in the wells was aspirated, and 100 μL of thiazolyl blue (MTT) dye (0.5 mg / mL) was added. The plate was then incubated for 4 hours for staining. Afterward, the MTT dye was aspirated, and 150 μL of dimethyl sulfoxide was added. The 96-well plate was shaken for 15 minutes to mix thoroughly before being read at 570 nm using a microplate reader. For the cytotoxicity assay, each sample was replicated three times.

[0229] Incubate with hydrogel film dressing extract for 24 hours. Figure 9 a), 48 hours Figure 9 b) and 72 hours ( Figure 9 c) Quantitative assay for cytotoxicity MTT assay as follows Figure 9 As shown, the tested hydrogel films loaded with polypeptide polymers did not exhibit significant cytotoxicity against human umbilical vein endothelial cells (HUVEC), NCTC clone 929 (L929), mouse embryonic fibroblasts (NIH-3T3), and African green monkey kidney fibroblasts (COS-7), suggesting that the hydrogel films loaded with polypeptide polymers have high biocompatibility.

[0230] Example 10: Hemolytic activity test of hydrogel film loaded with polypeptide polymer against erythrocytes

[0231] Hydrogel films were prepared using the polypeptide polymer obtained in Example 1, and their hemolytic activity against erythrocytes was tested.

[0232] Fresh red blood cells were obtained from 8-week-old SD rats and stored at 4°C for later use. For testing, sufficient fresh blood was taken, diluted with an appropriate amount of TBS, and centrifuged at 4000 rpm for 3 minutes. After discarding the supernatant, TBS was added again, the red blood cells at the bottom were mixed, and centrifugation was repeated three times. Then, TBS was added again to dilute the red blood cells to 5% for later use. The preparation method of the hydrogel film was similar to that described in Example 2. In short, 100 μL of the hydrogel film precursor solution (PEG solid content of 5.0 wt%) was placed in a 2.0 mL centrifuge tube and evaporated to remove ethanol under vacuum at 80°C for 10 minutes to obtain hydrogel films (PG hydrogel (PEG solid content of 5.0 wt%), PG-TA hydrogel (PEG solid content of 5.0 wt%, TA content of 1.0 wt%), and PG-TA-P hydrogel (PEG solid content of 5.0 wt%, TA content of 1.0 wt%, polypeptide polymer content of 400 μL / mg).

[0233] 0.5 mL of 5% red blood cell dilution was added to a centrifuge tube containing a hydrogel membrane. 0.1% polyethylene glycol octylphenyl ether (TX100) was used as a positive control, and pure TBS as a negative control. After incubation at 37°C for 1 hour, the tubes were centrifuged at 3700 rpm for 5 minutes. After photographing, 100 μL was transferred from each tube to a brand new 96-well plate, and the readings were taken at 405 nm using a microplate reader. The hemolysis rate % was calculated using the formula: (OD experimental group - ODTBS negative control) / (ODTX100 positive control - ODTBS negative control) × 100%. Each sample in the hemolysis activity test had three replicates.

[0234] The experimental results are as follows Figure 10 The results showed that the hydrogel film loaded with polypeptide polymers did not exhibit significant hemolytic activity in erythrocytes, demonstrating its good biocompatibility with erythrocytes.

[0235] Example 11: Hydrogel films loaded with polypeptide polymers scavenging intracellular reactive oxygen species

[0236] Hydrogel films were prepared using the polypeptide polymer prepared in Example 1, and their effect on eliminating reactive oxygen species inside RAW264.7 cells caused by endotoxins was tested.

[0237] RAW264.7 cells were grown at a rate of 3 × 10⁻⁶. 4 Cells were seeded at a density of 10 cells / well in 48-well cell culture plates and cultured for 24 hours. After washing once with PBS, cells were starved for 8 hours in serum-free medium. The medium was then discarded and replaced with serum-free DMEM medium containing lipopolysaccharide (LPS) (10 μg / mL) hydrogel film dressing extract, and cultured for 20 hours. Cells were washed once with PBS, and incubated for 30 minutes in serum-free medium containing 10 μM 2′,7′-dichlorofluorescein diacetate (DCFH-DA). After incubation at 37°C with Hochest 33342 (diluted 1:100 with PBS) for 10 minutes, cells were washed three times with PBS and observed using a fluorescence microscope. Quantitative analysis of fluorescence intensity was performed using ImageJ software.

[0238] The results are as follows Figure 12 As shown, LPS stimulation significantly increased the fluorescence intensity of 2′,7′-dichlorodihydrofluorescein (DCF), indicating an increase in reactive oxygen species (ROS) levels within macrophages. Incubation of macrophages with PG-TA and PG-TA-P hydrogel films significantly inhibited DCF fluorescence, demonstrating their ROS-inhibiting function.

[0239] Example 12: Hydrogel film loaded with polypeptide polymer for hemostasis in an acute liver hemorrhage model

[0240] The hemostatic effect of hydrogel films with different TA contents (0%, 0.25wt%, 0.5wt%, 1.0wt%, and 2.0wt%) (PEG solid content of 5% and polypeptide polymer content of 400 μg / mL) was tested, with Merocel hemostatic sponge (Medtronic product) used as a control.

[0241] The preparation methods for PG5-TA0.25-P, PG5-TA0.5-P, PG5-TA1.0-P, and PG5-TA2.0-P films were similar to those described in Example 2. The hydrogel films were fabricated into 10 mm circular patches. Eighteen male ICR mice were used to create a liver hemorrhage model.

[0242] Mice were anesthetized and restrained on the operating table. After disinfecting the abdominal skin with povidone-iodine, the liver was carefully exposed onto pre-weighed filter paper. A 3 mm deep and 8 mm long incision was made in the liver using a scalpel. Hemostasis was achieved using the aforementioned hydrogel film and Merocel hemostatic sponge, and the amount of bleeding was recorded over 240 seconds.

[0243] The experimental results are as follows Figure 13 As shown in Figure a, the PG-TA-P hydrogel film (PEG solid content 5%, TA content 1%, polypeptide polymer content 400 μL / mg) not only exhibits strong tissue adhesion during mechanical deformation, stretching, and bending, but also can be peeled off from the liver surface without residue after hemostasis. Figure 13 b and Figure 13 As shown in Figure c, the untreated control group (blank) experienced severe bleeding, with a blood loss of 482.27 ± 25.83 mg. Treatment with the PG-TA-P hydrogel film significantly reduced the blood loss to only 84.48 ± 6.79 mg, even surpassing the hemostatic effect of the commercial hemostatic sponge Medtronic Merocel (blood loss of 229.63 ± 18.78 mg). Hemostasis time recordings showed that the PG-TA-P hydrogel film treatment group achieved effective hemostasis within 15 seconds, while the untreated group and the Merocel-treated group both took more than 150 seconds. The PG-TA-P hydrogel film dressing is superior to Medtronic's Merocel product used in current clinical guidelines for wound hemostasis.

[0244] Example 13: Construction of a Diabetes Model

[0245] A diabetic model was induced by intraperitoneal injection of streptozotocin (STZ). Typically, male ICR mice (20 g) were fasted overnight (with normal water intake) and then intraperitoneally injected with STZ (130 mg / kg, dissolved in 0.1 M / citrate buffer, pH 4.5). Following STZ injection, mice continued to fast for 2 hours, with free access to food and water for the remainder of the experimental period. One week later, mice with blood glucose levels above 300 mg / dL for five consecutive days were identified as diabetic mice and used in subsequent experiments.

[0246] Example 14: Hydrogel film loaded with peptide polymers clears reactive oxygen species from wound sites in vivo

[0247] Infected diabetic wound (IDW) models were constructed as described in Examples 12 and 13. In the IDW model, the in vivo antioxidant capacity of the hydrogel film was evaluated using 2',7'-dichlorofluorescein diacetate (DCFH-DA) as a reactive oxygen species (ROS) probe.

[0248] Using physiological saline and Braun (B. Braun, ...) After treatment with PG-TA-P hydrogel film dressing for 24 hours, the wound was rinsed twice with PBS, then incubated with PBS containing 20 μM DCFH-DA for 30 minutes. In vivo ROS levels and ROS levels in wound tissue were assessed using an in vivo fluorescence imaging system (Clinx Science Instruments Co., Ltd., China) and a laser scanning confocal microscope (LSCM) (NIKON, AXR with Nikon spatial array confocal microscope, Japan).

[0249] The experimental results are as follows Figure 14 a and Figure 14 As shown in b, in vivo fluorescence imaging results confirmed that the ROS scavenging capacity of the PG-TA-P hydrogel film was significantly higher than that of physiological saline and B. braunsifen (B. braunsifen). The positive control used clinical wound gel dressings as outlined in the UK National Institute for Health and Care Excellence (NICE) guidelines for the treatment of acute and chronic wounds (MTG67). Quantitative fluorescence intensity analysis of ROS in wound tissue using fluorescence confocal microscopy confirmed that, compared to the saline group, PG-TA-P hydrogel film treatment significantly reduced ROS levels in wound tissue 24 hours after application, while Botansu did not show a significant reduction in ROS levels compared to the saline group. PG-TA-P hydrogel film dressings are superior to Botansu used in current clinical guidelines in effectively clearing reactive oxygen species from wound tissue.

[0250] Example 15: Hydrogel film loaded with peptide polymer for removing wound exudate

[0251] Infected diabetic wound (IDW) models were constructed as described in Examples 13 and 14, and the accumulation of exudate in vivo using hydrogel films was evaluated within the IDW model. Figure 15 As shown in a. 24 hours after infection, the wound was treated with physiological saline and Botanshu (B. Braun, ...). The wound was treated with PG-TA-P hydrogel film, and the weight of exudate was measured on days 0, 1, 3, and 5 post-treatment. The wound was covered with 3M Tegaderm dressing before measurement to avoid contamination, and a new dressing was applied after each measurement.

[0252] The experimental results are as follows Figure 15 b and Figure 15 As shown in c, on day 0 (24 hours post-infection), all treatment groups showed significant accumulation of wound secretions and exudates (~26.5 mg), attributed to a hyperglycemic microenvironment and infection. Notably, on day 1 post-treatment, the PG-TA-P hydrogel film dressing group showed a significant reduction in secretions and exudates (~4.1 mg), while the Botanshu (B. Braun, In the positive control group, the levels of secretions and exudates in the treatment group (~16.3 mg) and the saline treatment group (~28.8 mg) using the clinical wound gel dressing as described in the UK National Institute for Health and Care Excellence (NICE) guidelines for the treatment of acute and chronic wounds (MTG67) showed no significant decrease. By day 5 post-treatment, secretions and exudates in the PG-TA-P hydrogel film dressing group had almost completely disappeared (~1.7 mg); while the levels in the saline group showed almost no significant decrease (~26.5 mg); and only a slight reduction was observed in the Botansu treatment group (from ~16.3 mg to ~12.2 mg). The PG-TA-P hydrogel film dressing was superior to Botansu used in current clinical guidelines in clearing accumulated wound secretions and exudates.

[0253] Example 16: Construction and Treatment of Infected Diabetic Wound (IDW) Model

[0254] As in Example 13, a diabetic wound model was constructed. Staphylococcus aureus Sa USA300 LAC was cultured in LB medium at 37°C for 10 hours, washed three times with physiological saline, and then collected for later use.

[0255] Eighteen diabetic mice (weighing 20–22 g) were used to establish a full-thickness wound model of MRSA infection. The diabetic mice were anesthetized by intraperitoneal injection of sodium pentobarbital (a single dose of 80 mg / kg). After shaving the back hair, the skin was disinfected with povidone-iodine. 10 μl of Staphylococcus aureus suspension (1 × 10⁻⁶) was collected. 7CFU / mL was instilled into the wounds on both sides of the back via a 6mm diameter biopsy needle, and then the wounds were covered with 3M Tegaderm dressings to prevent contamination. Twenty-four hours post-infection, the mice were randomly assigned to different groups and received PBS, B. braunschweig (B. braunschweig), or other treatments. Mice were treated with PG-TA and PG-TA-P hydrogel film dressings. Twenty-four hours after treatment, mice were euthanized with sodium pentobarbital, and quantitative wound tissue was collected and homogenized using 0.1% Triton X-100. The homogenate was serially diluted and inoculated onto LB agar plates, incubated at 37°C for 14 hours to determine bacterial load.

[0256] For the healing of infected wounds in diabetic patients, a fixation ring is applied to the wound to prevent local skin contraction around the wound, thereby promoting healing through granulation tissue formation and epithelialization to better mimic the human wound healing process. The wound is treated with PBS and Botansu (B. braunsifen) 24 hours after infection. Mice were treated with PG-TA-P hydrogel film dressings and covered with 3M Tegaderm dressings to avoid contamination. Wound healing was observed on days 0, 1, 3, 5, 7, and 9. Mice were anesthetized and euthanized after treatment, and wound tissue was subsequently collected and fixed with 4% paraformaldehyde for histopathological and immunohistochemical examination.

[0257] The experimental results are as follows Figure 16 and 17 As shown, 24 hours after infection, the wound was treated with physiological saline (negative control) and Botanshu (B. Braun, ...). Positive controls were prepared using clinical wound gel dressings, PG-TA hydrogel film dressings, or PG-TA-P hydrogel film dressings, as outlined in the UK National Institute for Health and Care Excellence (NICE) guidelines for the treatment of acute and chronic wounds (MTG67). Treatment with PG-TA-P hydrogel film dressings significantly reduced the MRSA bacterial load in infected tissue (a reduction of 3.8 log CFUs compared to the saline treatment group), superior to clinical wound gel Botansu (which reduced the load by only 3.2 log CFUs). Figure 16 b and Figure 16 c). Gram-stained tissue sections showed that, compared with the saline treatment group, the PG-TA-P hydrogel film dressing group and the Botansu treatment group had significantly reduced MRSA bacteria counts in the wound, indicating that the PG-TA-P film effectively alleviated wound infection. Figure 16 d).

[0258] Furthermore, 5 days after treatment, the saline control group had the lowest wound closure rate, at 51.26±5.43%. The PG-TA-P hydrogel film dressing treatment group had a significantly better wound closure rate than the Botanshu treatment group, reaching 71.44±4.42%, while the Botanshu treatment group was 57.10±9.10%. Figure 17 a, Figure 17 b and Figure 17 c). On day 9 post-treatment, the PG-TA-P hydrogel film dressing significantly promoted wound healing, with a healing rate of 90.65±1.51%, significantly higher than that of the saline control group (66.60±7.80%) and the clinical wound gel Botanshu group (79.46±5.15%). Figure 17 c). Histological assessment included key indicators of wound healing, including epithelialization, granulation tissue thickness, and collagen deposition. For example... Figure 17 As shown in Figure d, the wounds in the PG-TA-P hydrogel film dressing treatment group and the Botanshu treatment group achieved complete epidermal coverage, while the saline control group showed fragmented coverage and a large amount of inflammatory response, indicating that the wounds had not yet healed.

[0259] All documents mentioned in this invention are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that after reading the foregoing teachings of this invention, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by the appended claims.

Claims

1. A hydrogel film loaded with an antibacterial agent, characterized in that, The constituent materials of the hydrogel film include: two or more polyethylene glycol monomers with different end groups, polyphenolic substances, and antibacterial agents; Wherein, the polyethylene glycol monomer is a linear, multi-arm polyethylene glycol monomer; and the number of arms is any value between 2 and 22; and each of the polyethylene glycol monomers is independently selected from the following group: m represents the chain length, where each m is an independent positive integer between 4 and 10000; q represents The number of times a unit is repeated; and q is an integer from 1 to 20; A is * indicates a connection point; R is an end group of a polyethylene glycol monomer; and each of them is independently a reactive group selected from the group consisting of: amino, C1-C15 alkylamino, acylhydrazine, C1-C15 alkylhydrazine, aldehyde, C1-C15 alkyl-aldehyde, mercapto, C1-C15 alkyl-mercapto, C2-C15 alkenyl, C1-C15 alkyl-norbornenyl, C1-C15 alkyl-maleimide, C1-C15 alkyl-aminothiol, C2-C15 alkynyl, and C1-C15 alkyl-azido. The end groups of two or more polyethylene glycol monomers with different end groups react to form a hydrogel network; and the polyphenolic substances and antibacterial agents are distributed on the hydrogel network.

2. The hydrogel film as described in claim 1, characterized in that, The polyphenols include natural and synthetic polyphenols; preferably, the polyphenols are selected from the group consisting of phenolic acids, flavonoids, stilbenes, lignans, tannins, or combinations thereof.

3. The hydrogel film as described in claim 1, characterized in that, The antibacterial agent is selected from the group consisting of: polypeptide polymers, β-lactam antibiotics (such as penicillins and cephalosporins), aminoglycoside antibiotics (such as streptomycin and amikacin), quinolone antibiotics (such as first-, second-, third-, and fourth-generation quinolones), macrolide antibiotics (such as erythromycin and azithromycin), polypeptide antibiotics (such as vancomycin and polymyxin B), tetracycline antibiotics (such as tetracycline and oxytetracycline), chloramphenicol antibiotics (such as chloramphenicol and thiamphenicol), sulfonamide antibiotics (such as sulfadiazine and sulfamethoxazole), rifamycin (such as rifampin and rifapentine), or combinations thereof; The polypeptide polymer is a homopolymer containing β-lysine residues or a copolymer containing β-lysine residues and β-glycine residues.

4. The hydrogel film as described in claim 1, characterized in that, The hydrogel film has one or more of the following characteristics: In the hydrogel film, the content of the polyphenolic substances is 0wt%-200wt%, based on the weight of the hydrogel film; and The antibacterial agent in the hydrogel film has a content of 0wt%-50wt%, based on the weight of the hydrogel film.

5. A method for preparing the hydrogel film according to claim 1, characterized in that, Including the following steps: (1) Provides a solution A of polyethylene glycol monomer A in a protic solvent, and a solution B of polyethylene glycol monomer B in a protic solvent, wherein the polyethylene glycol monomer A and polyethylene glycol monomer B are different from each other and are each independently selected from the group consisting of: m represents the chain length, and each m is an independent positive integer from 4 to 10000; q represents The number of times a unit is repeated; and q is an integer from 1 to 20; A is * indicates a connection point; R is an end group of a polyethylene glycol monomer; and each of them is independently a reactive group selected from the group consisting of: amino, C1-C15 alkylamino, acylhydrazine, C1-C15 alkylhydrazine, aldehyde, C1-C15 alkyl-aldehyde, mercapto, C1-C15 alkyl-mercapto, C2-C15 alkenyl, C1-C15 alkyl-norbornenyl, C1-C15 alkyl-maleimide, C1-C15 alkyl-aminothiol, C2-C15 alkynyl, and C1-C15 alkyl-azido. (2) The solutions A and B are mixed to form a hydrogel precursor solution; wherein the hydrogel precursor solution includes an unformed hydrogel precursor formed by polyethylene glycol monomer A and polyethylene glycol monomer B; (3) Add polyphenols and an antibacterial agent to the hydrogel precursor solution to obtain a hydrogel film precursor; and (4) Dry the hydrogel film precursor to obtain a hydrogel film.

6. The preparation method according to claim 5, characterized in that, In step (2), the mixing time is 1-48h; preferably 18-36h; more preferably 24-36h.

7. The preparation method according to claim 5, characterized in that, Step (4) also includes: Hydrogel film precursors are coated onto a surface by spraying, spin coating, or dip coating and then evaporated and dried to obtain a hydrogel film.

8. The use of the hydrogel film loaded with an antibacterial agent as described in claim 1, characterized in that, Used to prepare wound dressings.

9. The use as described in claim 8, characterized in that, The wound dressing described herein is used for hemostasis, physical isolation, chronic wound care, promoting wound healing, or a combination thereof.

10. A hydrogel film dressing, characterized in that, include: (1) The hydrogel film loaded with antibacterial agent according to claim 1, (2) Solid support; and (3)Optionally, other active ingredients that promote wound healing and / or recovery.

Citation Information

Patent Citations

  • Preparation method and application of beta-polypeptide polymer with low toxicity and high antibacterial activity

    CN117285707A